Roadmap Economic Impact & Funding Opportunities Dr Stephen Hillier

UK Government Academic & Technology base Industry + 14 other KTNS Chemistry Innovation KTN

Top 10 Deliverable: “Work with industry to establish where Smarter Chemistry-based technology can deliver cleaner, more effective, manufacturing processes” Smart Chemistry

Source: 2009 R&D Scoreboard of Top 850 UK Companies - published by BIS Bulk & Fine ChemicalsPharmaceutical & BiotechAgrochemicalsCoatings & LubricantsHome & Personal CareFood & DrinkMiningWater, Gas, ElectricityMetalsForestry & PaperConstruction & MaterialsElectronicsOil & FuelAerospace & Automotive Chemical Manufacture Process Technology Product Development Application & Formulation Skills Chemical Manufacture Process Technology Product Development Application & Formulation Skills Chemistry Engineering Biotechnology £113 bn £226 bn £523 bn GVA £270 bn UK Sales The size of the opportunity

Innovation Funding Landscape

Technology Strategy Board Concept to Commercialisation A strategy for business innovation, High-Value Manufacturing Maintaining or enhancing the international competitiveness of UK-based manufacturing industries, including aerospace, automotive, chemicals, pharmaceuticals and foods, through the development and application of innovative manufacturing technologies in product and process areas within and across sectors.

TSB – Challenge driven calls £5M funding call: Sustainable Manufacturing for the Process Industry Changing batch to continuous processes Novel catalysis Innovative heat management or input in process Solvent free reactions or use of novel solvents Process measurement and analysis Feasibility study projects Budget £0.4 million (projects to £100,000). Collaborative R&D projects Budget £4.6 million (projects to £1 million) CLOSED! Recent funding calls

Stage 1 CR&D Successes... Source: 2009 R&D Scoreboard of Top 850 UK Companies - published by BIS Bulk & Fine ChemicalsPharmaceutical & BiotechAgrochemicalsCoatings & LubricantsHome & Personal CareFood & DrinkMiningWater, Gas, ElectricityMetalsForestry & PaperConstruction & MaterialsElectronicsOil & FuelAerospace & Automotive

Call number 2? Sustainable Manufacturing 2?

Advancing the industrial application of synthetic biology AIM – to fund work into innovative industrial applications of synthetic biology Support early stage feasibility demonstrator studies £6.5m feasibility call TSB, BBSRC, EPSRC and Economic and Social Research Council (ESRC) Funded at up to 75% of total eligible costs Grants will not exceed £375k and the maximum project size is up to £500k. business-led and are open to businesses of any size and research organisations. Projects should last between 12 and 18 months. Competition opens on 8 October 2012

Autumn 2012

Alternative TSB Funding TSB Knowledge Transfer Partnerships (KTPs) – Expertise of Associate & academic is embedded into the company – Classical KTP 1-3 yr – Short KTP 6 months – 51 weeks – Costs approx £60K p.a. – company contribution 40% SME to 60% Large SMART Awards – Previously “Grant for R&D” single company scheme. SMEs. – Application review every 2 months

SMART Awards Proof of marketProof of concept Prototype development DurationTo 9 monthsTo 18 monthsTo 2 years Max grant£25K£100K£25K FundingTo 60% total project costs To 35% medium, 45% small

Final thoughts Awareness of funding calls Partnering Proposal review Public funding: Free advice & support

2,000 Companies 100 Universities 5,000 Individual members Further Partnering

Contact Details Dr Steve Hillier

Biomedical Catalyst The £180 million Biomedical Catalyst, announced by David Cameron in December 2011, will see the Medical Research Council and the Technology Strategy Board working together to provide responsive and effective support for the best life science opportunities arising in the UK. Support through the Biomedical Catalyst is available to UK businesses (SMEs) and academics looking to develop innovative solutions to healthcare challenges either individually or in collaboration. This joint programme between the MRC and TSB will offer three categories of grant: Feasibility Award Early Stage Award Late Stage Award The categories are designed to support the maturation of an idea from concept to commercialisation. This will create a pipeline of projects encompassing the early stage exploration of commercial and technical potential through to proving utility in the field (which may involve human clinical trials) and development prior to commercialisation. Applicants may apply for the award category most appropriate for their work without having received a prior award. Support will be available for projects arising from any sector or discipline that are aimed at addressing healthcare challenges. Example solutions may include (but are not limited to): stratified healthcare (both therapy and diagnostic components), regenerative medicine, diagnostics, eHealth and mHealth solutions, enabling medical technologies and devices. The Biomedical Catalyst will seek to support those opportunities which demonstrate the highest scientific and commercial potential irrespective of medical area. Please see the Technology Strategy Board healthcare page for more information about our work in this area. healthcare The Biomedical Catalyst will operate in response mode and will in essence be "always open". However to assist the processing of applications there will be key submission and assessment dates which will differ depending on the category of award and applicant type, please see the links/dates below for further details. The assessment of Early and Late Stage awards will culminate in a panel assessment for both academic and business led applications enabling funding decisions to be made three times a year.